Dr. Petrylak on the Utilization of Enfortumab Vedotin in MIBC

Daniel P. Petrylak, MD, professor of medicine and urology, coleader, Cancer Signaling Networks, Yale Cancer Center, discusses the utilization of enfortumab vedotin-ejfv (Padcev) in patients with muscle-invasive bladder cancer (MIBC).

The phase 1b/2 EV-103 trial (NCT03288545) investigated the use of enfortumab vedotin alone and in various combinations in patients with urothelial cancer. Cohort H featured patients with MIBC who were eligible for surgical resection but ineligible for cisplatin-based chemotherapy. These patients received 3 cycles of neoadjuvant enfortumab vedotin on days 1 and 8 of every 3-week cycle.

Preliminary analysis of this cohort showed that of the 22 patients enrolled, 36.4% achieved a pathologic complete response with no viable tumor present in the specimen cystectomy, Petrylak says. Moreover, 50% of patients experienced a reduction in tumor size, Petrylak explains.

Overall, enfortumab vedotin seems to have significant efficacy in this patient population, Petrylak concludes.